ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

ENDRA Life Sciences has initiated a review of strategic alternatives to maximize shareholder value. The company's Board of Directors will evaluate potential options including strategic investments, mergers, business combinations, and asset sales. ENDRA has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel in connection with this process. The review process has no set timetable for completion.